2024
Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers
Dey P, Kc M, Proussaloglou E, Khubchandani J, Kim L, Zanieski G, Park T, Lynch M, Gillego A, Valero M, Schneider E, Golshan M, Greenup R, Berger E. Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. Annals Of Surgical Oncology 2024, 1-8. PMID: 39240394, DOI: 10.1245/s10434-024-16124-9.Peer-Reviewed Original ResearchTriple-negative breast cancerClinically node-negativePathologically node-negativePN+ diseaseNode-negativeBreast cancerYears of ageNodal diseaseHR-/HER2Significant comorbiditiesEpidermal growth factor receptor 2-positiveOdds of node positivityRate of nodal diseaseTriple-positive breast cancerTriple positive breast cancerEarly-stage breast cancerHR-positive/HER2-negativePathologic nodal diseasePathologic nodal positivityPredictors of pN+T1a breast cancerHR-/HER2+Sentinel node biopsyNational Cancer DatabasePathologic nodal stage
2011
P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017).
De L, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017). Cancer Research 2011, 71: p2-08-02-p2-08-02. DOI: 10.1158/0008-5472.sabcs11-p2-08-02.Peer-Reviewed Original ResearchRadiographic complete responseNeoadjuvant systemic therapyInvasive breast cancerSystemic therapyBreast cancerHR-/HER2Systemic treatmentTumor gradePathologic complete response rateTumor phenotypeBasis of estrogenComplete response rateOperable breast cancerMulticenter retrospective studyNeoadjuvant systemic treatmentMorbidity of surgeryHER2 receptor statusPrediction of pCRBreast cancer subtypesMagnetic resonance imagingHR-HER2IHC phenotypeChemotherapy regimenNeoadjuvant chemotherapyTN subtype